Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR6INY)

Drug Name
DPC 423 Drug Info
Synonyms
DPC602; 228258-45-5; DPC-423; 209957-47-1; SCHEMBL3052253; CHEMBL176140; BDBM12657; ZINC1490578; 1H-Pyrazole-5-carboxamide,1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-; KB-65316; KB-76718; 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide; 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2-(methylsulfonyl)-[1,1-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
Indication
Disease Entry ICD 11 Status REF
Thrombosis DB61-GB90 Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
9895762
TTD Drug ID
DMR6INY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Coagulation factor Xa (F10)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apixaban DM89JLN Thrombosis DB61-GB90 Approved [3]
Rivaroxaban DMQMBZ1 Deep vein thrombosis BD71 Approved [4]
DU-176b DMCIJBH Atrial fibrillation BC81.3 Approved [5]
Emicizumab DM0AQ83 Factor VIII deficiency 3B10 Approved [6]
BETRIXABAN DM2C4RF Venous thromboembolism BD72 Approved [7]
Lmw heparin DMJPD06 Coagulation defect 3B10.0 Approved [8]
Nadroparin calcium DMBNKST Coagulation defect 3B10.0 Approved [9]
Fondaparinux sodium DMWS3FH Deep vein thrombosis BD71 Approved [10]
Danaparoid DM6CLBN Deep venous clot BD71 Approved [11]
Coagulation Factor IX DM8HBJI Haemophilia B 3B11.0 Approved [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor Xa (F10) TTCIHJA FA10_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012496)
2 The design and synthesis of noncovalent factor Xa inhibitors. Curr Top Med Chem. 2001 Jun;1(2):137-49.
3 Pfizer. Product Development Pipeline. March 31 2009.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
6 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
7 Company report (Portola)
8 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
9 Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
10 Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
11 Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
12 Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.